Ann Duerr

HVTN Core Operations, Fred Hutchinson Cancer Center, United States of America

Throughout her career, Dr. Duerr has been interested in the public health concerns of the developing world. She began her career doing field and bench research on malaria and schistosomiasis, and for more than 15 years she has focused on clinical and epidemiological studies of HIV infection.

Dr. Duerr is currently the Associate Director (Scientific Support) of the NIAID-supported HIV Vaccine Trials Network (HVTN). With more than 25 sites on 5 continents, the HVTN provides a clinical trials platform for the conduct of safety, immunogenicity, and efficacy studies of HIV vaccine candidates.

She also has a long-standing interest in research on women's health and
in complex humanitarian emergencies.

Any competing interests declared are displayed with individual evaluations.

Faculty Member: Infectious Diseases > HIV Infection & AIDS: Vaccines (since 10 November 2005)

All recent recommendations

• 8.2
  Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines.
  Recommended by Ann Duerr, Paul Goepfert with Anju Bansal, Holden Maecker with Laurel Nomura
  
• 3.2
  A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells.
  Recommended by Ann Duerr, James Tartaglia
  
• 3.2
  Estimating the benefit of an HIV-1 vaccine that reduces viral load set point.
  Recommended by James Tartaglia, Ann Duerr
  
• 3.0
  Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection.
  Recommended by Ann Duerr
  
• 3.0
  Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.
  Recommended by Ann Duerr
  
• 3.0
  Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women.
  Recommended by Ann Duerr